Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-06-21
2011-06-21
Goddard, Laura B (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07964349
ABSTRACT:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
REFERENCES:
patent: 2005/0272083 (2005-12-01), Seshagiri
patent: 25185/92 (1993-04-01), None
patent: 02/102976 (2002-12-01), None
Pao et al (PNAS, 2004, 101:13306-13311, IDS).
Paez et al (Science, 2004, 304:1497-1500).
Lynch et al (New England J of Medicine, May 2004, 350:2129-2139, IDS).
Riely et al (Clinical Cancer Research, 2006, 12:839-844, IDS).
Cohen et al (Clinical Cancer Research, 2005, 11:8105-8108).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s, IDS).
Frederick et al (Cancer Research, 2000, 60:1383-1387, IDS).
Cappuzzo et al (J Clinical Oncology, 2003, 14:2658-2663).
Dancey J. et al., Cancer Cell, 5(5):411-415 (2004).
Frederick L. et al., Cancer Research, 60(5):1383-1387 (2000).
Han Y. et al., Cancer Research, 56(17):3859-3861 (1996).
Han Y. et al., Oncology Research, 9(11-12):581-587 (1997).
Pedersen M., Int. J. of Cancer, 108(5):643-653 (2004).
Carlos L. Arteaga et al. (1997) Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with ATP binding site. J. Biol. Chem. 272(37): 23247-54.
Hui-Kuo G. Shu, et al. (1990) Tissue-specific transformation by epidermal growth factor receptor: A single point mutation within the ATP-binding pocket of theerbBproduct increases its intrinsic kinase activity and activates its sarcomagenic potential. Proc. Natl. Acad. Sci. USA 87: 9103-7.
Stephanie Blencke et al. (2003) Mutation of Threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitor. J. Biol. Chem. 278(17): 14535-40.
Johan F. Vansteenkiste (2004) Gefitinib (Iressa®): a novel treatment for non-small cell lung cancer. Expert Rev. Anticancer Ther. 4(1):5-17.
Pao et al. (PNAS, 2004, 101:13306-13311).
Riely et al. (Clinical Cancer Research, 2006, 12:839-844).
Greulich et al.,(PloS Medicine, 2005, 11: 1167-1176).
Tockman et al. (Cancer Res., 1992, 52: 2711s-2718s).
Slamon et al., (Science vol. 235, Jan. 1987, pp. 177-182).
Bowie et al.,(Science, 1990, 247: 1306-1310).
Sakurada et al., “Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations” Clinical Lung Cancer (2006), vol. 7 pp. S138-S144.
Kobayashi et al., “EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib” N. Engl. J. Med (2005) vol. 352 No. 8, pp. 786-792.
Lynch et al., “Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib” N. Engl. J. Med (2004), vol. 350 No. 21, pp. 2129-2139.
Tokumo et al., “Double mutation and gene copy number of EGFR is gefitinib refractory non-small-cell lung cancer” Lung Cancer (2006) vol. 53, pp. 117-121.
Fitch et al., Genetics of Dark Skin in Mice, Gene & Development 17:214-228 (2003).
U.S. Appl. No. 11/894,160, filed Aug. 20, 2007, Office Action mailed Feb. 18, 2010.
Fitch et al., Gentics of Dark Skin in Mice, Gene & Development 17:214-228 (2003).
Choong, et al. Nature Clinical Practice Oncology 3:50-57 (2006).
Cohen, et al. Clinical Cancer Research 11:8105-8108 (2005).
U.S. Appl. No. 11/294,621, filed Dec. 5, 2005, Office Action mailed Feb. 7, 2007.
U.S. Appl. No. 11/294,621, filed Dec. 5, 2005, Office Action mailed Jul. 13, 2006.
U.S. Appl. No. 11/894,135, filed Aug. 20, 2007, Office Action mailed Nov. 30, 2009.
U.S. Appl. No. 11/894,135, filed Aug. 20, 2007, Office Action mailed Feb. 9, 2009.
Cappuzzo et al., J. Clinical Oncology, 14:2658-2663 (2003).
U.S. Appl. No. 11/894,160 filed Aug. 20, 2007, Office Action mailed Jul. 20, 2010.
Bell Daphne Winifred
Haber Daniel A.
Janne Pasi Antero
Johnston Bruce E.
Lynch Thomas J.
Dana-Farber Cancer Institute Inc.
Goddard Laura B
Nixon & Peabody LLP
The General Hospital Corporation
LandOfFree
Method to determine responsiveness of cancer to epidermal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to determine responsiveness of cancer to epidermal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to determine responsiveness of cancer to epidermal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670999